Abstract
Objective(s)
Study Design
Results
Conclusions
Implications
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionReferences
- A retrospective chart review of contraceptive use among adolescents with opioid use disorder.J Pediatr Adolesc Gynecol. 2018; 31 (doi:): 122-127https://doi.org/10.1016/j.jpag.2017.11.002
- Family planning in substance use disorder treatment centers: opportunities and challenges.Subst Use Misuse. 2016; 51 (doi:): 1477-1483https://doi.org/10.1080/10826084.2016.1188944
- Contraceptive use and pregnancy outcomes among opioid drug-using women: a retrospective cohort study.PLoS One. 2015; 10 (doi:)e0116231https://doi.org/10.1371/journal.pone.0116231
- Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review.Prev Med. Nov. 2015; 80 (doi:): 23-31https://doi.org/10.1016/j.ypmed.2015.04.008
- Innovative approaches to reduce unintended pregnancy and improve access to contraception among women who use opioids.Prev Med. Nov. 2019; 128 (doi:)105794https://doi.org/10.1016/j.ypmed.2019.105794
- Declines in unintended pregnancy in the United States, 2008-2011.N Engl J Med. 2016; 374 (Mar 3doi:): 843-852https://doi.org/10.1056/NEJMsa1506575
- Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017.JAMA. 2021; 325 (doi:): 146-155https://doi.org/10.1001/jama.2020
American college of obstetricians and gynecologists. committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. Aug 2017;130(2):e81-e94. doi: 10.1097/aog.0000000000002235
- Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance.J Addict Med. 2017; 11 (May/Jundoi:): 178-190https://doi.org/10.1097/adm.0000000000000308
- CDC grand rounds: public health strategies to prevent neonatal abstinence syndrome.MMWR Morb Mortal Wkly Rep. 2017; 66 (Published 2017 Mar 10doi:): 242-245https://doi.org/10.15585/mmwr.mm6609a2
- Committee on fetus and newborn, committee on substance use and prevention. Neonatal opioid withdrawal syndrome.Pediatrics. 2020; 146 (doi:)e2020029074https://doi.org/10.1542/peds.2020-029074
Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder TIP 63 treatment improvement protocol for healthcare and addiction professionals, policymakers, patients, and families. Substance Abuse and Mental Health Services Administration. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Available at: https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf; 2021 [accessed 24 January 2022].
- White Paper: IBM MarketScan Research Databases for life sciences researchers.IBM Watson Health, 2018 (Available at)
- The teen access and quality initiative: improving adolescent reproductive health best practices in publicly funded health centers.J Community Health. 2020; 45 (doi:): 615-625https://doi.org/10.1007/s10900-019-00781-z
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association; 2013.
U.S. Federal Food and Drug Administration. Information about Medication-Assisted Treatment (MAT). Available at: https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat; Last updated February 14, 2019 [accessed 30 July 2021]
Trussell J, Aiken ARA, Micks E, Guthrie KA. Efficacy, safety, and personal considerations. In: Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowal D, eds. Contraceptive technology. 21st ed. New York, NY: Ayer Company Publishers, Inc.; 2018.
- US Medical Eligibility Criteria for Contraceptive Use.MMWR Recomm Rep. 2016; 65 (2016Doi): 1-103https://doi.org/10.15585/mmwr.rr6503a1
- A Simple Sequentially Rejective Multiple Test Procedure.Scandinavian J Statistics. 1979; 6 (Available at): 65-70
- Contraceptive counseling: best practices to ensure quality communication and enable effective contraceptive use.Clin Obstet Gynecol. 2014; 57 (Doi): 659-673https://doi.org/10.1097/GRF.0000000000000059
- Provider bias in long-acting reversible contraception (LARC) promotion and removal: perceptions of young adult women.Am J Public Health. 2016; 106 (Doi): 1932-1937https://doi.org/10.2105/AJPH.2016.303393
Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020 Apr 27;2020:10.31478/202004b. doi: 10.31478/202004b. PMID: 35291732
- Buprenorphine treatment divide by race/ethnicity and payment.JAMA Psychiatry. 2019; 76 (Doi): 979-981https://doi.org/10.1001/jamapsychiatry.2019.0876
- Treatment outcome disparities for opioid users: Are there racial and ethnic differences in treatment completion across large US metropolitan areas?.Drug Alcohol Depend. 2018; 190 (Doi): 170-178https://doi.org/10.1016/j.drugalcdep.2018.06.006
United States Government Accountability Office. Opioid Addiction: Laws, regulations and other factors can affect medication-assisted treatment access. Available at: https://www.gao.gov/assets/gao-16-833.pdf September 2016. [Accessed 16 June 2022].
- Factors affecting contraception access and use in patients with opioid use disorder.J Clin Pharmacol. 2020; 60 (SupplDoi): S63-S73https://doi.org/10.1002/jcph.1772
- Perceived barriers and facilitators to contraceptive use among women veterans accessing the veterans affairs healthcare system.Womens Health Issues. 2020; 30 (Doi): 57-63https://doi.org/10.1016/j.whi.2019.08.005
- Improving access to long-acting contraceptive methods and reducing unplanned pregnancy among women with substance use disorders.Subst Abuse. 2016; 10 (SupplDoi): 27-33https://doi.org/10.4137/sart.S34555
- Reproductive-age women’s experience of accessing treatment for opioid use disorder: “We Don’t Do That Here”.Womens Health Issues. 2021; 31 (Doi): 455-461https://doi.org/10.1016/j.whi.2021.03.010
- Barriers and facilitators to the use of medications for opioid use disorder: a rapid review.J Gen Intern Med. 2020; 35 (SupplDoi): 954-963https://doi.org/10.1007/s11606-020-06257-4
Orgera K, Tolbert J. Key facts about uninsured adults with opioid use disorder. Henry J Kaiser Family Foundation, Available at: https://files.kff.org/attachment/Data-Note-Key-Facts-about-Uninsured-Adults-with-Opioid-Use-Disorder; 2019.
- Revisiting Churn: An Early Understanding of State-Level Health Coverage Transitions Under the ACA.National Academy for State Health Policy, 2016 (Available at)
- Health Insurance Coverage Among Young Adults Aged 19 to 34: 2018 and 2019.U.S. Department of Commerce, U.S. Census Bureau, 2020 (Available at)
- Condoms for dual protection: patterns of use with highly effective contraceptive methods.Public Health Rep. 2010; 125 (Doi): 208-217https://doi.org/10.1177/003335491012500209
- Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: Summary guidance from CDC and the U.S. Department of Health and Human Services.MMWR Recomm Rep. 2012; 61: 1-46
Article info
Publication history
Footnotes
Conflict of interest: The author declares no conflict of interest.
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).
By conducting a ≥ 6 year continuous enrollment, we identified 116 and 62 commercially-insured women and 97 and 243 Medicaid-insured women who used LARC and who had sterilization, respectively, that would not have been identified had we chosen a ≥ 3 year continuous enrollment. Sample sizes with continuous enrollment ≥ 6 years for commercially-insured and Medicaid-insured women (3085 and 3841, respectively) were smaller than ≥ 3 years (6603 and 35,418, respectively). Women prescribed MOUD made up 41% of each sample size with ≥ 6 years and ≥ 3 years continuous enrollment, except among Medicaid-insured women with ≥ 3 year continuous enrollment where they made up 60%.
